A Phase 3 interventional study of Buprenorphine and Buprenorphine in Back Pain Lower Back Chronic, sponsored by Purdue Pharma LP. Terminated at 85 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-03.
Sponsored by Purdue Pharma LP (part of Knoa Pharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing buprenorphine in Low Back Pain — none open to participants now, none under way, none of them phase 3. Buprenorphine · Low Back Pain.
Among the 13 studies testing buprenorphine in Low Back Pain, this one is the 3rd largest by enrollment, is one of 2 that started in 2004, is one of 10 in phase 3, and was the 1st registered.
2,927 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.
Browse Low Back Pain studies →None of the 13 studies testing buprenorphine in Low Back Pain is open now. The open studies under Low Back Pain, anywhere →
Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 333 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 660 is above the median of 60 across 2,366 interventional studies indexed under Low Back Pain.
Median enrollment 302 across the 13 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 6 most frequent:
This study is registered under Purdue Pharma LP, one of the names counted as Knoa Pharma. Under that name alone:
Purdue Pharma LP is the lead sponsor of 58 studies on the registry; none are open to participants now.
Knoa Pharma has 7 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing buprenorphine in Low Back Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) 20 in comparison to the buprenorphine transdermal system (BTDS) 5 and oxycodone immediate-release in subjects with moderate to severe low back pain currently treated with oral opioids. The double-blind treatment intervention duration is 12 weeks during which time supplemental analgesic medication (acetaminophen, ibuprofen) will be provided to all subjects in addition to study drug.
Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-specific exclusion/inclusion criteria may apply.
Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
Drug: Buprenorphine
Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
Drug: Buprenorphine
Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
Drug: Oxycodone Immediate-Release
Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
Also known as: Butrans™
Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
Also known as: Butrans™
Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).
Average Pain Over the Last 24 Hours Score at Weeks 4, 8, and 12.
Subjects were evaluated during the double-blind phase for "average pain over the last 24 hours" prior to the study visits. Pain scale is 11 points (0 = no pain to 10 = pain as bad as you can imagine)
Time frame: Last 24 hours score at weeks 4, 8, 12 of the double-blind phase
Mean Daily Number of Supplemental Analgesic Tablets
The mean daily number of tablets of supplemental analgesic medications used during the double-blind phase
Time frame: Double-blind phase (84 days)
Oswestry Disability Index (ODI) Score (V 2.0)
The ODI (version 2) is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0 = good to 5 = worse). (Note: A higher score represents greater disability.)
Time frame: Weeks 4, 8, 12
The Sleep Disturbance Subscale in the MOS-Sleep Scale at Weeks 4, 8, and 12.
The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity/ optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath). Question 1 is scored on a scale of 1 to 5 and Questions 3 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.
Time frame: Weeks 4, 8, 12 of the double-blind phase
The study began with first patient first visit (FPFV) on 25-Feb-2004 to last patient last visit (LPLV) on 23-Sep-2005, at 75 medical/research sites in the United States.
| Milestone | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release |
|---|---|---|---|
| Started | 221 | 219 | 220 |
| Completed | 128 | 146 | 159 |
| Not completed | 93 | 73 | 61 |
| Withdrew: Withdrawal by subject | 11 | 7 | 5 |
| Withdrew: Adverse event | 14 | 29 | 16 |
| Withdrew: Lost to follow-up | 7 | 6 | 10 |
| Withdrew: Administrative | 9 | 6 | 14 |
| Withdrew: Lack of efficacy | 52 | 25 | 16 |
Subjects were evaluated during the double-blind phase for "average pain over the last 24 hours" prior to the study visits. Pain scale is 11 points (0 = no pain to 10 = pain as bad as you can imagine)
| units on a scale | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release |
|---|---|---|---|
| Screening | 6.36 ± 0.075 | 6.46 ± 0.084 | 6.46 ± 0.079 |
| Prerandomization | 2.84 ± 0.075 | 2.91 ± 0.075 | 2.74 ± 0.074 |
| Week 4 | 3.79 ± 0.149 | 3.40 ± 0.128 | 3.14 ± 0.125 |
| Week 8 | 3.83 ± 0.162 | 3.35 ± 0.140 | 3.24 ± 0.145 |
| Week 12 | 4.02 ± 0.179 | 3.35 ± 0.139 | 3.26 ± 0.152 |
The mean daily number of tablets of supplemental analgesic medications used during the double-blind phase
| tablets | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release |
|---|---|---|---|
| Mean Daily Number of Supplemental Analgesic Tablets | 3.8 ± 0.12 | 3.3 ± 0.13 | 3.5 ± .13 |
The ODI (version 2) is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0 = good to 5 = worse). (Note: A higher score represents greater disability.)
| units on a scale | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release |
|---|---|---|---|
| Week 4 | 34.80 ± 1.066 | 33.04 ± 1.019 | 30.79 ± 1.124 |
| Week 8 | 35.69 ± 1.245 | 34.27 ± 1.094 | 31.64 ± 1.165 |
| Week 12 | 36.30 ± 1.392 | 33.06 ± 1.231 | 32.96 ± 1.243 |
The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity/ optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath). Question 1 is scored on a scale of 1 to 5 and Questions 3 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.
| units on a scale | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release |
|---|---|---|---|
| Week 4 | 40.67 ± 2.025 | 34.65 ± 1.607 | 38.10 ± 1.788 |
| Week 8 | 42.28 ± 2.264 | 35.69 ± 1.721 | 39.17 ± 1.924 |
| Week 12 | 40.85 ± 2.376 | 33.65 ± 1.941 | 41.60 ± 2.205 |
Collected over Adverse events occurring after the signing of the informed consent up to end of study and 7 days after, discontinuation, or serious AEs occurring up to 30 days following the last study visit were followed until the AE or sequelae resolved or stabilized.. Non-serious events are listed at a 4.50% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind BTDS 5 | — | 6/221 (2.7%) | 54/221 (24.4%) |
| Double-blind BTDS 20 | — | 7/219 (3.2%) | 118/219 (53.9%) |
| Double-blind Oxycodone Immediate-Release | — | 9/220 (4.1%) | 93/220 (42.3%) |
| Open-label Run-in Period, BTDS 10/20 | — | 10/1,160 (0.9%) | 389/1,160 (33.5%) |
| Event | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release | Open-label Run-in Period, BTDS 10/20 |
|---|---|---|---|---|
| PancreatitisGastrointestinal disorders | 2/221 | 0/219 | 0/220 | 0/1160 |
| HematemesisGastrointestinal disorders | 0/221 | 1/219 | 0/220 | 0/1160 |
| Intractable vomitingGastrointestinal disorders | 0/221 | 1/219 | 0/220 | 0/1160 |
| Chest pressureGeneral disorders | 0/221 | 1/219 | 0/220 | 0/1160 |
| Acute cholecystitisHepatobiliary disorders | 0/221 | 1/219 | 0/220 | 0/1160 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/221 | 1/219 | 0/220 | 0/1160 |
| Abdominal aortic aneurysmVascular disorders | 0/221 | 1/219 | 0/220 | 0/1160 |
| NauseaGastrointestinal disorders | 0/221 | 1/219 | 0/220 | 0/1160 |
| VomitingGastrointestinal disorders | 0/221 | 1/219 | 0/220 | 0/1160 |
| Increased total bilirubinInvestigations | 0/221 | 1/219 | 0/220 | 0/1160 |
| Event | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release | Open-label Run-in Period, BTDS 10/20 |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 18/221 | 27/219 | 18/220 | 174/1160 |
| Application site pruritusGeneral disorders | 12/221 | 29/219 | 20/220 | 102/1160 |
| HeadacheNervous system disorders | 12/221 | 25/219 | 21/220 | 124/1160 |
| Application site erythemaGeneral disorders | 10/221 | 22/219 | 19/220 | 38/1160 |
| Application site rashGeneral disorders | 17/221 | 20/219 | 13/220 | 38/1160 |
| ConstipationGastrointestinal disorders | 7/221 | 14/219 | 14/220 | 46/1160 |
| SomnolenceNervous system disorders | 4/221 | 10/219 | 11/220 | 67/1160 |
| DizzinessNervous system disorders | 5/221 | 10/219 | 8/220 | 62/1160 |
| Vomiting NOSGastrointestinal disorders | 5/221 | 11/219 | 9/220 | 60/1160 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/221 | 10/219 | 4/220 | 8/1160 |
| Age Continuous(years) | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release | Total |
|---|---|---|---|---|
| Mean | 50.2 ± 12.88 | 50.4 ± 11.93 | 49.5 ± 12.37 | 50.0 ± 12.39 |
| Sex: Female, Male(Participants) | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release | Total |
|---|---|---|---|---|
| Female | 101 | 113 | 100 | 314 |
| Male | 120 | 106 | 120 | 346 |
The record gives a start of Feb 2004, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Buprenorphine